EU's retsregler for lægemidler og medicinsk udstyr garanterer høje kvalitets- og sikkerhedsstandarder. Lægemidler godkendes i EU af Europa-Kommissionen eller nationalt af EU-landenes kompetente myndigheder og overvåges i deres levetid via EU's system for lægemiddelovervågning. Medicinsk udstyr d...
Antimikrobiel resistens (AMR) udgør en stigende trussel mod den globale sundhed. EU følger en "One Health"-tilgang til problemet, hvor der tages hensyn til menneskers sundhed, dyrs sundhed og miljøet. Vi undersøgte, hvordan Kommissionen og relevante EU-agenturer forvaltede deres støtte til medle...
Der er risici forbundet med alle former for behandling og pleje. Lægemidler har bivirkninger, læger fejlordinerer nogle gange, og patienter kan få en infektion under behandlingen. Minimering af disse risici og garanti for, at patienter får en sundhedspleje af høj kvalitet, der er sikker, effekti...
This report provides a technical review of the current body of knowledge regarding synthetic cannabinoids that are monitored by the EU Early Warning System. The aim of this report is to strengthen situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare for, and...
This report, focusing on a single country, provides an analysis of current drug supply models and the related violence and exploitation of vulnerable groups in Denmark. Recent years have seen a growth in criminals’ exploitation of vulnerable groups for drug-related crimes. This development appea...
Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live, with European countries having to introduce unprecedented measures to protect public health. As with all areas of life, drug consumption, related harms and drug markets have been impacted, as have the services ...
The purpose of these guidelines is to ensure compliance with the scope and requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) in respect to the risk assessment procedure for and reporting on new psychoactive substances....